A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
← catalyst calendarNCT07217015 · readout ≤ 314 d
Sponsored by Kymera Therapeutics, Inc. (industry) · KYMR — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
200estimated
Sites
68
Countries
Australia, Canada, Czechia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-24 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Interventions
- Drug: KT-621
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in Eczema Area and Severity Index (EASI) score
measured From baseline through Week 16
Permalink · KYMR's whole pipeline · Catalyst calendar · Every registered study · What changed